Evidence map›Paper›PMID 30564886›Full record

ReviewEuropean archives of psychiatry and clinical neuroscience2019

Cannabis and mental illness: a review.

Darby J E Lowe, Julia D Sasiadek, Alexandria S Coles, Tony P George

Open access · greenAbstract readReview
In one paragraph

Review in European archives of psychiatry and clinical neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 8 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 8 syntheses or guidelines pooled it, 240 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Darby J E LoweAddictions Division, Centre for Addiction and Mental Health (CAMH), University of Toronto, 100 Stokes Street, BGB 3288, Toronto, ON, M6J 1H4, USA.
Julia D SasiadekAddictions Division, Centre for Addiction and Mental Health (CAMH), University of Toronto, 100 Stokes Street, BGB 3288, Toronto, ON, M6J 1H4, USA.
Alexandria S ColesAddictions Division, Centre for Addiction and Mental Health (CAMH), University of Toronto, 100 Stokes Street, BGB 3288, Toronto, ON, M6J 1H4, USA.
Tony P GeorgeAddictions Division, Centre for Addiction and Mental Health (CAMH), University of Toronto, 100 Stokes Street, BGB 3288, Toronto, ON, M6J 1H4, USA. tony.george@camh.ca.
Addiction Research Foundation · US

Funding

Effects of rTMS on Cannabis Use and Cognitive Outcomes in SchizophreniaR21DA043949 · NIDA · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI GEORGE, TONY P · 2017 to 2018
$286k
National Institute on Drug Abuse R21DA043949NIDA NIH HHS R21 DA043949
6 · The paper itself

Abstract

With the increasing push to legalize cannabis in Western nations, there is a need to gage the potential impact of this policy change on vulnerable populations, such as those with mental illness, including schizophrenia, mood, and anxiety disorders. This is particularly important as there are strong motives in these individuals to seek short-term reward (e.g., "getting high"). Nonetheless, data to support the beneficial effects of cannabis use in psychiatric populations are limited, and potential harms in patients with psychotic and mood disorders have been increasingly documented. This article reviews the effects of cannabis in people with mental illness. Then, we provide a reconciliation of the addiction vulnerability and allostatic hypotheses to explain co-morbidity addiction in mentally ill cannabis users, as well as to further aid in developing a rational framework for the assessment and treatment of problematic cannabis use in these patients.

Indexed as

Anxiety DisordersBipolar DisorderCannabinoidsHumansMajor Depressive DisorderMarijuana UseSchizophreniaStress Disorders, Post-TraumaticCannabinoidsAddictionAnxiety disordersCannabisHarmsLegalizationMood disordersPost-traumatic stress disorderSchizophreniaTherapeutics

Identifiers

PMID30564886
PMCPMC6397076
OpenAlexW2904833627

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.